Topic: disease prevention
With three positive phase 3 trials in hand, Eli Lilly heads for the FDA with migraine drug galcanezumab.
Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.
Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials.
New research from Smith & Nephew showed that hospital-acquired pressure ulcers could be significantly decreased via an ulcer prevention program.